NEXIEN BIOPHARMA, INC.: 10-Q filed 2023-05-17
What NEXIEN BIOPHARMA, INC. reported in its quarterly report filed 2023-05-17 (fiscal Q3 2023): 17 published measures, 55 facts as tagged in accession 0001493152-23-017925.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-05-17
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001493152-23-017925 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NEXIEN BIOPHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 58,197 | USD | |
| At 2022-06-30 | 124,518 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 288,496 | USD | |
| At 2022-06-30 | 242,123 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | -230,299 | USD | |
| At 2022-12-31 | -202,321 | USD | |
| At 2022-09-30 | -160,604 | USD | |
| At 2022-06-30 | -117,605 | USD | |
| At 2022-03-31 | -63,260 | USD | |
| At 2021-12-31 | -62,425 | USD | |
| At 2021-09-30 | -39,986 | USD | |
| At 2021-06-30 | -13,775 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 54,207 | USD | |
| At 2022-06-30 | 116,898 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -79,853 | USD | 90 |
| 2022-07-01 to 2023-03-31 | -268,319 | USD | 274 |
| 2022-10-01 to 2022-12-31 | -93,592 | USD | 92 |
| 2022-07-01 to 2022-09-30 | -94,874 | USD | 92 |
| 2022-01-01 to 2022-03-31 | -187,451 | USD | 90 |
| 2021-07-01 to 2022-03-31 | -529,356 | USD | 274 |
| 2021-10-01 to 2021-12-31 | -220,194 | USD | 92 |
| 2021-07-01 to 2021-09-30 | -121,711 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2023-03-31 | -62,691 | USD | 274 |
| 2021-07-01 to 2022-03-31 | -51,824 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2022-03-31 | 174,000 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | -11,201,777 | USD | |
| At 2022-06-30 | -10,933,458 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 62,637,365 | shares | 90 |
| 2022-07-01 to 2023-03-31 | 61,868,350 | shares | 274 |
| 2022-01-01 to 2022-03-31 | 59,080,529 | shares | 90 |
| 2021-07-01 to 2022-03-31 | 57,009,375 | shares | 274 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -0.001 | USD/shares | 90 |
| 2022-07-01 to 2023-03-31 | -0.004 | USD/shares | 274 |
| 2022-01-01 to 2022-03-31 | -0.003 | USD/shares | 90 |
| 2021-07-01 to 2022-03-31 | -0.01 | USD/shares | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 58,197 | USD | |
| At 2022-06-30 | 124,518 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 288,496 | USD | |
| At 2022-06-30 | 242,123 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 69,375 | USD | 90 |
| 2022-07-01 to 2023-03-31 | 216,722 | USD | 274 |
| 2022-01-01 to 2022-03-31 | 164,403 | USD | 90 |
| 2021-07-01 to 2022-03-31 | 492,838 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 62,772,196 | shares | |
| At 2022-06-30 | 60,522,196 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 10,914,451 | USD | |
| At 2022-06-30 | 10,759,051 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 60,615 | USD | 90 |
| 2022-07-01 to 2023-03-31 | 186,542 | USD | 274 |
| 2022-01-01 to 2022-03-31 | 153,113 | USD | 90 |
| 2021-07-01 to 2022-03-31 | 464,068 | USD | 274 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -10,478 | USD | 90 |
| 2022-07-01 to 2023-03-31 | -51,597 | USD | 274 |
| 2022-01-01 to 2022-03-31 | -23,048 | USD | 90 |
| 2021-07-01 to 2022-03-31 | -36,518 | USD | 274 |
Inspect the source
- Entity
- NEXIEN BIOPHARMA, INC. / CIK 0001625288
- Captured
- 2026-09-21T17:21:50.748Z
- SEC response SHA-256
044a00232373cfad706e13d40a0fcc524943f52c3deb14bbc85e1072ff58fe5c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001625288.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))